SOAT1 and neoplasm: Targeting FGFR3 with specific inhibitors such as Small Molecule Tyrosine Kinase Inhibitors (Erdafitinib, Infigratinib) or monoclonal antibodies (Vofatamab) has shown efficacy in inhibiting aberrant signaling pathways like MAPK-ERK and JAK-STAT, thereby suppressing tumor growth [42].